| Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation S Gur, PJ Kadowitz, WJG Hellstrom Expert opinion on drug safety 12 (1), 81-90, 2013 | 102 | 2013 |
| Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options S Gur, M Limin, WJG Hellstrom Expert opinion on pharmacotherapy 12 (6), 931-944, 2011 | 96 | 2011 |
| A comprehensive review of metabolic syndrome affecting erectile dysfunction E Kaya, SC Sikka, S Gur The journal of sexual medicine 12 (4), 856-875, 2015 | 91 | 2015 |
| The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin‐induced diabetic rats: Preventive versus curative treatment MF Usta, M Kendirci, S Gur, NA Foxwell, TJ Bivalacqua, S Cellek, ... The journal of sexual medicine 3 (2), 242-252, 2006 | 87 | 2006 |
| The effects of chronic 5‐alpha‐reductase inhibitor (dutasteride) treatment on rat erectile function MR Pinsky, S Gur, AJ Tracey, A Harbin, WJG Hellstrom The journal of sexual medicine 8 (11), 3066-3074, 2011 | 74 | 2011 |
| Pharmacological management of Peyronie’s disease LW Trost, S Gur, WJG Hellstrom Drugs 67, 527-545, 2007 | 58 | 2007 |
| Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension S Gur, P J Kadowitz, A Gokce, S C Sikka, U Lokman, W JG Hellstrom Current drug metabolism 14 (2), 265-269, 2013 | 56 | 2013 |
| The relationship between the type of penile abnormality and penile vascular status in patients with Peyronie's disease M Kendirci, S Nowfar, S Gur, GW Jabren, SC Sikka, WJG Hellstrom The Journal of urology 174 (2), 632-635, 2005 | 48 | 2005 |
| The role of PDE5 inhibitors and the NO/cGMP pathway in cancer TC Peak, A Richman, S Gur, FA Yafi, WJG Hellstrom Sexual medicine reviews 4 (1), 74-84, 2016 | 46 | 2016 |
| Aging and sexual health: getting to the problem E Kaya, SC Sikka, PJ Kadowitz, S Gur The Aging Male 20 (2), 65-80, 2017 | 44 | 2017 |
| Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy ÇV Öztekin, S Gur, NA Abdulkadir, U Lokman, AÖ Akdemir, M Cetinkaya, ... The Journal of Sexual Medicine 9 (7), 1773-1781, 2012 | 41 | 2012 |
| Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction S Gur, P J Kadowitz, W JG Hellstrom Current pharmaceutical design 16 (14), 1619-1633, 2010 | 40 | 2010 |
| Chronic inhibition of nitric‐oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil S Gur, PJ Kadowitz, L Gurkan, S Chandra, SY DeWitt, A Harbin, SC Sikka, ... BJU international 106 (1), 78-83, 2010 | 39 | 2010 |
| Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview S Gur, PJ Kadowitz, WJG Hellstrom Current pharmaceutical design 13 (31), 3236-3244, 2007 | 38 | 2007 |
| Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum S Gur, PJ Kadowitz, L Trost, WJG Hellstrom The Journal of urology 178 (4), 1543-1548, 2007 | 38 | 2007 |
| A critical appraisal of erectile function in animal models of diabetes mellitus S Gur, PJ Kadowitz, WJG Hellstrom International journal of andrology 32 (2), 93-114, 2009 | 37 | 2009 |
| Advances in stem cell therapy for erectile dysfunction S Gur, AB Abdel-Mageed, SC Sikka, WJG Hellstrom Expert opinion on biological therapy 18 (11), 1137-1150, 2018 | 35 | 2018 |
| Review of erectile dysfunction in diabetic animal models S Gur, T C Peak, P J Kadowitz, S C Sikka, W JG Hellstrom Current diabetes reviews 10 (1), 61-73, 2014 | 34 | 2014 |
| Poly (Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury M Kendirci, Z Zsengellér, TJ Bivalacqua, S Gur, MF Usta, M Chen, ... The Journal of urology 174 (5), 2054-2059, 2005 | 34 | 2005 |
| Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress S Gur, SC Sikka, WJG Hellstrom Expert opinion on investigational drugs 17 (6), 855-864, 2008 | 31 | 2008 |
